S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Modern Day Options Trading For Beginners! (Ad)pixel
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:SBBP

Strongbridge Biopharma - SBBP Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.95
▼
$2.06
50-Day Range
$1.89
▼
$2.29
52-Week Range
$1.85
▼
$4.26
Volume
684,684 shs
Average Volume
866,464 shs
Market Capitalization
$135.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SBBP stock logo

About Strongbridge Biopharma (NASDAQ:SBBP) Stock

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBBP Stock News Headlines

January 11, 2023 | marketwatch.com
Day One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenib
September 22, 2022 | markets.businessinsider.com
Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients
March 28, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
September 23, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
August 31, 2021 | finance.yahoo.com
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
August 5, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 2, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
July 29, 2021 | finance.yahoo.com
Strongbridge Biopharma plc to Report Second Quarter 2021 Financial Results on August 5, 2021
March 28, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
July 29, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
July 28, 2021 | nasdaq.com
Strongbridge Biopharma's (NASDAQ:SBBP) Stock Price Has Reduced 48% In The Past Three Years
July 27, 2021 | finance.yahoo.com
Strongbridge Biopharma (SBBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
July 26, 2021 | msn.com
BRIEF-Strongbridge Biopharma Plc, Unit, Avenue Venture Opportunities Fund Enter Amendment To A Term Loan Agreement
July 15, 2021 | nasdaq.com
Strongbridge Biopharma plc Ordinary Shares (SBBP)
July 13, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve
June 29, 2021 | markets.businessinsider.com
Tudor Capital Europe LLP : Form 8.3 - Strongbridge Biopharma Plc
June 3, 2021 | finance.yahoo.com
Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome
May 29, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Strongbridge Biopharma plc - SBBP
May 29, 2021 | businesswire.com
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...
May 28, 2021 | finance.yahoo.com
STRONGBRIDGE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Strongbridge Biopharma plc - SBBP
May 25, 2021 | businesswire.com
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are ...
May 24, 2021 | benzinga.com
Strongbridge Biopharma Merger Investigation:...
May 24, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: WeissLaw LLP Investigates Strongbridge Biopharma plc
May 24, 2021 | finance.yahoo.com
Strongbridge Biopharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Strongbridge Biopharma plc Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – SBBP
May 24, 2021 | finance.yahoo.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Strongbridge Biopharma plc (Nasdaq - SBBP)
May 24, 2021 | markets.businessinsider.com
Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
May 24, 2021 | msn.com
Why Strongbridge Biopharma's Stock Is Trading Higher Today
See More Headlines
Receive SBBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Strongbridge Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SBBP Company Calendar

Last Earnings
8/05/2021
Today
3/27/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SBBP
CUSIP
N/A
CIK
1634432
Web
www.strongbridgebio.com
Phone
(610) 254-9200
Fax
N/A
Employees
72
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-45,080,000.00
Net Margins
-115.67%
Pretax Margin
N/A
Return on Equity
-66.82%
Return on Assets
-36.21%

Debt

Debt-to-Equity Ratio
0.38
Current Ratio
3.00
Quick Ratio
2.95

Sales & Book Value

Annual Sales
$30.73 million
Price / Sales
4.41
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.98 per share
Price / Book
2.04

Miscellaneous

Outstanding Shares
67,829,000
Free Float
N/A
Market Cap
$135.66 million
Optionable
Optionable
Beta
1.58

Key Executives

  • John H. Johnson
    Chief Executive Officer & Director
  • Richard S. Kollender
    President & Chief Financial Officer
  • Fredric Cohen
    Chief Medical Officer
  • Brian Conner
    Chief Compliance Officer
  • Peter J. Valentinsson
    Senior Vice President-Global Technical Operations

Key Competitors

View All Competitors













SBBP Stock - Frequently Asked Questions

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings data on Thursday, August, 5th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma (NASDAQ:SBBP) has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45,080,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The official website for the company is www.strongbridgebio.com. The biotechnology company can be reached via phone at (610) 254-9200 or via email at investors@strongbridgebio.com.

This page (NASDAQ:SBBP) was last updated on 3/28/2023 by MarketBeat.com Staff